North Star Asset Management Inc. Has $34.16 Million Position in Veeva Systems Inc. $VEEV

North Star Asset Management Inc. raised its holdings in Veeva Systems Inc. (NYSE:VEEV) by 0.9% during the second quarter, Holdings Channel.com reports. The fund owned 118,614 shares of the technology company’s stock after purchasing an additional 1,034 shares during the period. Veeva Systems comprises about 1.4% of North Star Asset Management Inc.’s holdings, making the stock its 16th largest holding. North Star Asset Management Inc.’s holdings in Veeva Systems were worth $34,158,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Columbia Bank boosted its position in shares of Veeva Systems by 4.5% in the 2nd quarter. Columbia Bank now owns 4,466 shares of the technology company’s stock worth $1,253,000 after purchasing an additional 192 shares during the last quarter. Steward Partners Investment Advisory LLC grew its position in shares of Veeva Systems by 9.6% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 8,546 shares of the technology company’s stock worth $2,461,000 after buying an additional 746 shares during the period. CreativeOne Wealth LLC increased its stake in shares of Veeva Systems by 139.8% in the 2nd quarter. CreativeOne Wealth LLC now owns 2,640 shares of the technology company’s stock valued at $760,000 after acquiring an additional 1,539 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in shares of Veeva Systems in the 2nd quarter valued at approximately $1,947,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in Veeva Systems by 1.9% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 736,493 shares of the technology company’s stock worth $212,095,000 after acquiring an additional 13,804 shares during the last quarter. Institutional investors own 88.20% of the company’s stock.

Veeva Systems Trading Down 3.3%

VEEV stock opened at $236.10 on Tuesday. The stock has a 50-day moving average price of $286.95 and a two-hundred day moving average price of $279.11. Veeva Systems Inc. has a 1 year low of $201.54 and a 1 year high of $310.50. The stock has a market cap of $38.70 billion, a PE ratio of 48.48, a price-to-earnings-growth ratio of 2.22 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Thursday, November 20th. The technology company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. The company had revenue of $811.24 million for the quarter, compared to analyst estimates of $792.37 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.75 earnings per share. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS. Q4 2026 guidance at 1.920-1.920 EPS. On average, analysts forecast that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Jonathan Faddis sold 14,595 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $300.00, for a total transaction of $4,378,500.00. Following the completion of the transaction, the senior vice president directly owned 8,588 shares of the company’s stock, valued at $2,576,400. This trade represents a 62.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of Veeva Systems stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the completion of the sale, the insider owned 25,325 shares in the company, valued at $7,765,151.50. This trade represents a 19.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 24,665 shares of company stock valued at $7,438,000 in the last quarter. 10.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

VEEV has been the subject of several recent analyst reports. TD Cowen raised shares of Veeva Systems from a “hold” rating to a “buy” rating and upped their target price for the company from $297.00 to $380.00 in a research note on Tuesday, October 7th. Evercore ISI upped their price objective on shares of Veeva Systems from $285.00 to $295.00 and gave the company an “in-line” rating in a research report on Thursday, August 28th. BMO Capital Markets started coverage on Veeva Systems in a research note on Thursday, November 13th. They set a “market perform” rating and a $300.00 price objective on the stock. BTIG Research reissued a “buy” rating and issued a $340.00 target price on shares of Veeva Systems in a research note on Friday. Finally, UBS Group lowered their price target on Veeva Systems from $310.00 to $280.00 and set a “neutral” rating for the company in a report on Friday. Nineteen equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $305.62.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.